Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02636283 · ClinicalTrials.gov registry record · Phase 2
Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
A Phase 2 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02636283: Clinical Trial Phase 2 study, sponsored by University of Minnesota.
NCT02636283 is a Phase 2 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02636283, a Phase 2 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
Primary Outcome
Time in minutes on a standardized treadmill test to initiation of pain and time until pain requires patient to stop walking
Interventions
- DRUG Entresto
- DRUG Placebo group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-12-31 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 2 |
Why NCT02636283 stopped before completion
NCT02636283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Entresto is the first listed.
NCT02636283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02636283 about?
NCT02636283 is a clinical study titled "Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease". This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
What is the current status of trial NCT02636283?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-12-31. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT02636283?
The interventions under investigation include: Entresto (DRUG), Placebo group (DRUG).
Who is sponsoring clinical trial NCT02636283?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02636283's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI